Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.
Polman C; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Selmaj K; Uitdehaag BM; Dahms S; Bauer L; Pohl C; Sandbrink R; Journal Of Neurology, 2008, vol. 255, issue 4, p 480, ISSN 03405354. ISBN 03405354.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef